Targets › MAGE-A4
2 programs from 2 companies in 3 trials: 3 Phase 1; Oncology; next expected readout Sep 2027.
Open in Phaseline: the race on MAGE-A4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Immatics Biotechnologies | IMA401 TCER® (T cell engineered receptor) targeting MAGE-A4 and/or MAGE-A8 | MAGE-A4, MAGE-A8 | Phase 1 | Refractory Cancer | Sep 2027 |
| USWM CT | Autologous genetically modified MAGE-A4ᶜ¹º³²T cells T cell receptor (TCR) engineered T cells targeting MAGE-A4 | MAGE-A4 | Phase 1 | Urinary Bladder Cancer | Sep 2032 |
Refractory Cancer (2) Urinary Bladder Cancer (1)
other (1), mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.